A Study of Vemurafenib and Obinutuzumab Compared to Cladribine and Rituximab in People With Hairy Cell Leukemia (HCL)
for Hairy Cell Leukemia
Drug: Rituximab
10 locations incl. Boston
Sponsor: Memorial Sloan Kettering Cancer Center
Sex: All·Age: 18+
Code: NCT06561360·Phase 2·Recruiting